Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dementia01:30

Dementia

482
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
482
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Reviewer Comment on Martineau et al. "Barriers to Clinical Care in Frontotemporal Dementia and Related Disorders: A Cross-Sectional Survey of Patients and Caregivers' Journey in the Canadian Healthcare System".

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same author

Longevity and cognitive resilience in a Colombian family carrying the <i>APOE</i> ε2 variant.

Journal of Alzheimer's disease : JAD·2026
Same author

Impact of "Kids' Court" on traffic infraction recidivism in Dar es Salaam: A novel approach to a troublesome problem.

Injury·2026
Same author

Phenotypic diversity of frontotemporal lobar degeneration in two novel GRN variants from Colombia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

The exposome of brain aging across 34 countries.

Nature medicine·2026
Same author

Plasma extracellular vesicles from APOE3 Christchurch carriers display a protective phenotype in early stages of autosomal dominant Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

相关实验视频

Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K

技术与痴呆症 会议前会议

Juliana Moreno Rada1,2,3,4, Luisa María Zapata Saldarriaga1,2,3,4, Elkin Garcia-Cifuentes4

  • 1Universidad de Antioquia, Medellín, Antioquia, Colombia.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 23, 2025
PubMed
概括

脑电图 (EEG) 和双任务 (DT) 范式有效地识别了临床前自体主导阿尔茨海默氏病 (ADAD) 携带者. 这些非侵入性生物标志物在患有PSEN1-E280A变种的个体中显示出早期检测的前景.

更多相关视频

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

相关实验视频

Last Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K
The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

科学领域:

  • 神经科学是一个神经科学.
  • 生物标志物开发 生物标志物开发
  • 遗传学 遗传学 是一个

背景情况:

  • 哥伦比亚有已知的最大的自体主导性阿尔茨海默病 (ADAD) 亲属,与PSEN1-E280A遗传变异有关.
  • 脑电图 (EEG) 是一种不足以利用的生物标志物,用于了解ADAD中的大脑功能和电生理学变化.
  • 双任务 (DT) 范式,特别是在运动任务期间,对于检测神经退行性疾病中的认知障碍是有价值的.

研究的目的:

  • 调查EEG与DT范式相结合的实用性,作为识别临床前ADAD的生物标志物.
  • 使用基于EEG的DT测量方法,区分PSEN1-E280A变体的无症状携带者和非携带者.
  • 确定用于早期ADAD检测的非侵入性,便携式工具的可行性.

主要方法:

  • 在单任务和双任务 (运动认知) 条件下,从无症状的PSEN1-E280A载体 (n=37) 和非载体 (n=42) 收集了EEG数据.
  • 双重任务成本 (DTC) 是使用前部和中心EEG信号的光谱和神经动态特征来计算的.
  • 统计分析涉及科恩-D效应大小和曼-惠特尼U测试来比较组.

主要成果:

  • 在特定的DT任务 (DTS7,DTS1,DTAN) 中,在各种EEG频段 (Beta,Theta,Alpha) 和区域 (前部,中部) 观察到显著的效果大小.
  • 在Beta1/Beta3带 (正面) 中的和Beta2 (C4) 中的相对功率显示出显著的差异.
  • 在DTS7期间,前部区域的Theta和Alpha2调制也显著.

结论:

  • 实验方法成功地提取了区分PSEN1-E280A载体与非载体的EEG信息.
  • 阿尔法和β频段的DTC值,特别是在前部和中部区域,表明对临床前认知和运动差异的敏感性.
  • 这种EEG和DT范式为早期ADAD载体识别提供了一个有希望的,非侵入性的工具.